Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the target of a significant decline in short interest in February. As of February 28th, there was short interest totalling 1,120,000 shares, a decline of 13.2% from the February 13th total of 1,290,000 shares. Based on an average daily trading volume, of 158,600 shares, the days-to-cover ratio is currently 7.1 days. Currently, 2.5% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Lifesci Capital raised Aura Biosciences to a "strong-buy" rating in a research note on Friday, January 31st. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Aura Biosciences presently has an average rating of "Buy" and an average target price of $23.00.

Aura Biosciences Stock Up 1.1 %

Shares of NASDAQ AURA traded up $0.08 during midday trading on Friday, reaching $7.50. The company had a trading volume of 282,589 shares, compared to its average volume of 169,641. Aura Biosciences has a one year low of $6.63 and a one year high of $12.38. The firm's fifty day moving average price is $7.66 and its 200-day moving average price is $8.67. The stock has a market cap of $374.63 million, a PE ratio of -4.34 and a beta of 0.30.

Insider Buying and Selling

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the transaction, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 23,045 shares of company stock worth $177,242 over the last ninety days. 5.40% of the stock is owned by corporate insiders.

Remove Ads

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of AURA. Charles Schwab Investment Management Inc. lifted its stake in shares of Aura Biosciences by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company's stock valued at $1,233,000 after acquiring an additional 3,612 shares during the last quarter. State Street Corp lifted its stake in shares of Aura Biosciences by 3.7% in the 3rd quarter. State Street Corp now owns 754,803 shares of the company's stock valued at $6,725,000 after acquiring an additional 26,841 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Aura Biosciences in the 3rd quarter valued at about $1,037,000. Barclays PLC lifted its stake in shares of Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company's stock valued at $544,000 after acquiring an additional 43,897 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Aura Biosciences by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock valued at $8,990,000 after acquiring an additional 39,379 shares during the last quarter. Institutional investors own 96.75% of the company's stock.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.